News

AVI BioPharma has announced presentation of data regarding the company’s antisense technology for control of the immune response in hemorrhagic virus infections, including Ebola and Marburg virus, at

The FDA has accepted for filing Mylan’s abbreviated new drug application (ANDA) for Glatiramer Acetate Injection (20mg/mL), a generic version of Teva’s Copaxone. The product is indicated for

MedAssurant has acquired Catalyst Information Technologies (Catalyst Technologies). The combined teams will offer and provide to customers the expanded toolset immediately. Reportedly, the acquisition, which closed effective September

Adamas Pharmaceuticals’ vitro study of its triple combination antiviral drug (TCAD) therapy showed greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double

Tobira Therapeutics has revealed results from an in-vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL), using

Alcon has entered into an agreement to acquire ESBATech. Alcon will pay ESBATech shareholders $150m in cash at closing, plus contingent payments of up to $439m based upon

Nektar Therapeutics’ clinical study data demonstrated that the oral tablet formulation of NKTR-118 has favorable systemic bioavailability and a low risk for mediating significant drug-drug interactions. NKTR-118 is

Gilead Sciences (Gilead) has published data from DAR-311 (DORADO), a phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) – darusentan, as an add-on

Roche’s two new observational studies concluded that influenza patients treated with Tamiflu had significantly higher survival rates than untreated patients. The studies, examining nearly 1,000 people, analysed outcomes